Hesperos, Inc.
Orlando, FL
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 12501 Research Pkwy #100, Orlando, FL 32826, USA
- Website
- hesperosinc.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $32,235 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Hesperos, Inc. Hesperos Inc. Division, a for-profit research organization based in Orlando, Florida, develops and commercializes microphysiological systems (organ-on-a-chip platforms) for preclinical drug testing, disease modeling, and toxicity screening. The company operates as a prime recipient on federal research grants and holds a single federal contract prime award; it does not subcontract on federal prime contracts. Hesperos competes in full-and-open procurements without set-aside designation.
The company's federal footprint is entirely concentrated within the National Institutes of Health. The National Center for Advancing Translational Sciences (NCATS) anchors 5 grants with $302 thousand in combined potential value, while the National Institute on Aging (4 awards), the National Heart Lung and Blood Institute (2 awards), the National Institute of Environmental Health Sciences (2 awards), the National Institute of Allergy and Infectious Diseases (1 award), and the National Institute on Drug Abuse (1 award) round out the active portfolio. These NIH divisions account for 82% of recent awards by count and 100% by combined potential value.
Representative work spans human-cell-based disease modeling. A $1 million Phase II direct award from NIAID (September 2026–August 2028) funds expanded implementation of a human-based malaria-on-a-chip phenotypic model for evaluating therapeutic efficacy and off-target toxicity in Plasmodium falciparum infection, structured as a project grant under CFDA 93.855. Two cooperative agreements and a project grant from NCATS (April 2024–May 2029) support development of a human neuromuscular junction platform to evaluate botulinum toxin potency and establish FDA-qualified assay methods as a replacement for the mouse lethality bioassay. A $32.2 thousand purchase order from NIH's Office of Logistics and Acquisition Operations (February 2024–February 2025) procured goods or services in support of preclinical screening activities. Hesperos traces its technology to a patented NMJ model licensed from University of Central Florida researcher Hickman; the company was founded by Hickman and Michael Shuler, a recognized founder of the body-on-a-chip field.
Activity is sparse — 17 total awards over ten years, with three in 2024 and one in 2026. Two awards reach ultimate completion inside the next twenty-four months, representing minimal recompete exposure. Combined obligated dollars ($43.4 million) substantially exceed combined potential value ($434 thousand), reflecting upfront disbursement on multi-year grants.
Quick answers
Is Hesperos, Inc. registered in SAM.gov?
Yes. Hesperos, Inc.'s SAM.gov registration is active through December 4, 2026.
What is Hesperos, Inc.'s CAGE code?
Hesperos, Inc.'s CAGE code is 79R15, and its Unique Entity ID (UEI) is R1LSLA5YJMJ9.
How much has Hesperos, Inc. received in federal contracts?
Federal contracts obligated $32,235 to Hesperos, Inc. in fiscal years 2023 through 2027.
What is Hesperos, Inc.'s most recent federal award?
Hesperos, Inc.'s most recent federal grant award is Expanded implementation of a human-based malaria-on-a-chip phenotypic disease model for the evaluation of therapeutic… (R44AI197758), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2026.
On GovTribe
See Hesperos, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors